PTX
PRESCIENT THERAPEUTICS LIMITED
$0.0560
▼ -3.45%
Market cap
$64M
Turnover
$34,470
Last price
$0.0560
Day change
-3.45%
Announcements
15
Range, past year
Open 0.048 · Low 0.040 · Now 0.056 · High 0.125
Open PTX in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
PTX momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
32/100
Wyckoff phase
Accumulation8d
Trend stage
Neutral
1 Day
-3.4%
1 Week
+0.0%
1 Month
-3.4%
1 Year
+19.1%
RSI
46
Avg daily range
6.2%
PRESCIENT THERAPEUTICS LIMITED scores 32 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 8 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently outperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -30.6%
- High volatility (ATR 6.2%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
PTX announcements
Recent price-sensitive releases.
- 2026-11-12 Prescient receives $3.4 million R&D Tax Refund Periodic Reports - Other | Company Administration - Other
- 2026-10-13 September 2026 Quarterly Update and Appendix 4C Commitments Test Entity - First Quarter Activity Report | Web Cast | Commitments Test Entity - First Quarter Cashflow Report
- 2026-09-23 PTX Successfully Completes $6m Raise Via SPP and Placement Placement | Trading Halt Lifted | Security Purchase Plan
- 2026-09-21 Trading Halt Trading Halt
- 2026-09-15 Prescient Therapeutics - Extension of Share Purchase Plan Web Cast | Security Purchase Plan
- 2026-09-08 Prescient Therapeutics - Extension of Share Purchase Plan Web Cast | Security Purchase Plan
- 2026-09-02 PTX-100 CTCL Phase 2a study reaches review milestone Web Cast | Progress Report
More Health Care stocks
Most traded in the same sector.